Propanc Biopharma, Inc. Common Stock Cash Flow Conversion Efficiency
Propanc Biopharma, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.70 Million) by net assets ($9.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Propanc Biopharma, Inc. Common Stock (2010–2026)
Cash flow conversion efficiency of Propanc Biopharma, Inc. Common Stock from 2010 to 2026. This chart illustrates how Propanc Biopharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PPCB stock price for real-time trading data and today's change.
Propanc Biopharma, Inc. Common Stock Cash Flow Conversion Ratio Explained
Propanc Biopharma, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Propanc Biopharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Propanc Biopharma, Inc. Common Stock (PPCB) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Belmont Resources Inc
V:BEA
|
-0.038x |
|
Ducon Infratechnologies Limited
NSE:DUCON
|
0.034x |
|
Traws Pharma Inc
NASDAQ:TRAW
|
-4.438x |
|
First Helium Inc
V:HELI
|
0.009x |
|
STREAMPLAY STUDIO LTD.
F:GIX0
|
N/A |
|
HELIX Resources Ltd
AU:HLX
|
-0.027x |
|
Bindi Metals Ltd
AU:BIM
|
-0.099x |
|
Evolution Energy Minerals Ltd
AU:EV1
|
-0.274x |
Annual Cash Flow Conversion Efficiency for Propanc Biopharma, Inc. Common Stock (2010–2026)
The table below shows the annual cash flow conversion efficiency of Propanc Biopharma, Inc. Common Stock from 2010 to 2026. Review PPCB cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $9.40 Million | $-5.68 Million | -0.604x | -1974.52% |
| 2025-06-30 | $13.91 Million | $-405.17K | -0.029x | -111.77% |
| 2024-06-30 | $-3.78 Million | $-935.12K | 0.247x | -30.21% |
| 2023-06-30 | $-3.12 Million | $-1.11 Million | 0.355x | -25.36% |
| 2022-06-30 | $-3.02 Million | $-1.44 Million | 0.475x | +27.23% |
| 2021-06-30 | $-3.07 Million | $-1.15 Million | 0.373x | -26.50% |
| 2020-06-30 | $-3.64 Million | $-1.85 Million | 0.508x | +6.05% |
| 2019-06-30 | $-4.30 Million | $-2.06 Million | 0.479x | +48.50% |
| 2018-06-30 | $-6.75 Million | $-2.18 Million | 0.323x | -18.43% |
| 2017-06-30 | $-5.44 Million | $-2.15 Million | 0.395x | -78.87% |
| 2016-06-30 | $-2.57 Million | $-4.80 Million | 1.871x | +300.52% |
| 2015-06-30 | $-3.05 Million | $-1.43 Million | 0.467x | +190.54% |
| 2014-06-30 | $-1.41 Million | $-226.44K | 0.161x | -0.95% |
| 2013-06-30 | $-792.48K | $-128.65K | 0.162x | -48.72% |
| 2012-06-30 | $-537.92K | $-170.28K | 0.317x | +338.36% |
| 2011-06-30 | $10.51 Million | $-1.40 Million | -0.133x | -112.96% |
| 2010-06-30 | $-186.90K | $-191.51K | 1.025x | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more